1. Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia. (9th November 2016) Authors: Pearce, K. F.; Balavarca, Y.; Norden, J.; Jackson, G.; Holler, E.; Dressel, R.; Greinix, H.; Toubert, A.; Gluckman, E.; Hromadnikova, I.; Sedlacek, P.; Wolff, D.; Holtick, U.; Bickeböller, H.; Dickinson, A. M. Journal: International journal of immunogenetics Issue: Volume 43:Number 6(2016:Dec.) Page Start: 404 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1184: PHASE I TRIAL OF MB-CART2019.1 IN PATIENTES WITH RELAPSED OR REFRATORY B-CELL NON-HODGKIN LYMPHOMA: 2 YEAR FOLLOW-UP REPORT. (23rd June 2022) Authors: Borchmann, P.; Lohneis, A.; Gödel, P.; Balke-Want, H.; Schmid, C.; Ayuk, F.; Holtkamp, S.; Hanssens, L.; Zadoyan, G.; Friedrichs, B.; Assenmacher, M.; Bürger, I.; Schneider, D.; Overstijns, T.; Scheid, C.; Holtick, U.; Miltenyi, S.; Hallek, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1070 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY. (23rd June 2022) Authors: Derigs, P.; Bethge, W.; Holtick, U.; von Tresckow, B.; Ayuk, F.; Penack, O.; Vucinic, V.; von Bonin, M.; Baldus, C.; Mougiakakos, D.; Wulf, G.; Schnetzke, U.; Stelljes, M.; Thomas, S.; Schroers, R.; Kroeger, N.; Dreger, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE. (23rd June 2022) Authors: Bücklein, V.; Perez, A.; Iacoboni, G.; Rejeski, K.; Holtick, U.; Penack, O.; Kharboutli, S.; Blumenberg, V.; Ackermann, J.; Frölich, L.; Johnson, G.; Patel, K.; Arciola, B.; Schmidt, C.; Albanyan, O.; Gödel, P.; Hoster, E.; Bullinger, L.; Mackensen, A.; Locke, F. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors. (December 2022) Authors: Jimeno, A.; Miselis, N.R.; Park, J.C.; Jennings, J.; Dhani, N.; Holtick, U.; Iams, W.T.; Rodabaugh, K.; Nair, N.; Kornacker, M.; Loughhead, S.M.; Bernstein, H.; Zwirtes, R.; Ji, R.R.; Warren, M.; Sharei, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗